$WOK

WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026

WORK Medical Technology Group (Nasdaq: WOK) said it will conduct a 1-for-100 reverse stock split of its Class A and Class B ordinary shares effective June 18, 2026. Class A shares are expected to trade on a post-split basis that day under symbol WOK with a new CUSIP. It had 241.65M Class A shares outstanding; about 2.42M are expected after the split.

Original reporting
Published Jun 16, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026 — source image
Decision brief

The 30-second read

$WOKNeutralMed
01

Why it matters

The reverse split will reduce the number of shares outstanding by consolidating 100 shares into 1, with fractional shares rounded up, and will update the CUSIP while keeping the Nasdaq symbol WOK.

02

Market read

This is a time-specific corporate action that can drive mechanical price changes and short-term trading volatility around the June 18 open.

03

What to watch

Traders should watch for any concurrent disclosures (financing, delisting risk, or updated risk factors) not included here, since the release is limited to the split mechanics.

Relevance 6/10Novelty 8/10Timing: Effective June 18, 2026; post-consolidation trading begins at the open.

Background

WORK Medical Technology Group LTD (Nasdaq: WOK) is a China-focused medical device supplier; this release announces a reverse stock split of its Class A and Class B ordinary shares.

Company-level read

Ticker impact

$WOKNeutralMedium confidence
Context

WORK Medical announced a 1-for-100 reverse stock split effective June 18, 2026, with post-split trading at the open.

Expected impact

Near-term volatility possible around the June 18 open due to mechanical price adjustment and investor positioning.

Evidence & confidence

The filing is a concrete corporate-action event with an explicit effective date and trading start time, but it does not provide new fundamentals (earnings, guidance, financing, or regulatory outcomes).

Market effects

Limited direct read-across to medical device peers; impact is primarily company-specific corporate-action mechanics.

Minimal; the company operates in China but the event is a Nasdaq-listed corporate action.

Low; no cross-border deal, regulatory ruling, or supply-chain disruption is disclosed.

Counterpoint

The reverse split may be purely compliance/structural (e.g., maintaining listing requirements) and not necessarily a signal of worsening operations.

Key entities

  • WORK Medical Technology Group LTD

    Nasdaq-listed medical device supplier announcing a 1-for-100 reverse stock split effective June 18, 2026.

  • VStock Transfer, LLC

    Named transfer agent for shareholder questions regarding the reverse stock split.

Related articles

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

$BKRMed

Baker Hughes (BKR) Lands Multi-Year Contract with Pakistan’s OGDC

Baker Hughes (BKR) secured a multi-year contract with Pakistan's OGDC to enhance production from mature oil and gas fields. The deal involves assessing 120 wells and providing tailored redevelopment plans. Baker Hughes aims to use AI and other technologies to improve flow assurance and restore production. The contract aligns with Baker Hughes' strategy to diversify revenue and reduce reliance on short-term drilling cycles, as evidenced by a 49% YoY increase in orders to $10.5 billion in Q2. Howe

$AAPLMed

Tim Cook Delivered a 2,720% Total Return Over 15 Years. Here's Whether John Ternus Can Do the Same for Apple Investors.

Tim Cook stepped down as Apple CEO after 15 years, delivering 2,720% total returns. New CEO John Ternus faces challenges, including margin pressure from rising memory costs. Apple is set to launch new iPhone models this week. iPhone sales grew over 20% in recent quarters, but management expects slower growth. Apple stock fell on margin concerns despite briefly surpassing $5 trillion.